{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:ema:blincyto:2:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Ablincyto%3A2%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002106,
    "timestamp_received": "2026-10-16T22:58:34.585017+00:00Z",
    "timestamp_returned": "2026-10-16T22:58:34.587123+00:00Z",
    "trace_id": "f763276f-768a-4bba-916c-fe95ebc129e0"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:ema:blincyto:2:0",
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-08-29:0",
          "type": "Contribution",
          "description": "On 2025-02-10, the EMA published an EPAR - Assessment report - Variation that recommended revising this approval's from being indicated for pediatric patients aged 1 year or older to 1 month or older.",
          "date": "2025-08-29",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2025-01-23:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2025-01-23",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        },
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:blincyto",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Blincyto (blinatumomab) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Amgen Europe B.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Blincyto",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "blinatumomab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2015-12-07",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2025-07-23",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:46",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C3167",
          "conceptType": "Disease",
          "name": "Acute Lymphoblastic Leukemia",
          "mappings": [
            {
              "relation": "narrowMatch",
              "coding": {
                "id": "coding:oncotree:BLL",
                "code": "BLL",
                "name": "B-Lymphoblastic Leukemia/Lymphoma",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=B-Lymphoblastic+Leukemia%2FLymphoma+%28BLL%29"
                ]
              }
            },
            {
              "relation": "narrowMatch",
              "coding": {
                "id": "coding:oncotree:TLL",
                "code": "TLL",
                "name": "T-Lymphoblastic Leukemia/Lymphoma",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=T-Lymphoblastic+Leukemia%2FLymphoma+%28TLL%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": false,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C3167",
            "code": "C3167",
            "name": "Acute Lymphoblastic Leukemia",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3167"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C62528",
          "conceptType": "Therapy",
          "name": "Blinatumomab",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:1597258",
                "code": "1597258",
                "name": "blinatumomab",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1597258"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:45892531",
                "code": "45892531",
                "name": "blinatumomab",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/45892531"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "CD19 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Immunotherapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C62528",
            "code": "C62528",
            "name": "Blinatumomab",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:14",
                "present": true,
                "subject": {
                  "id": "bmkr:14",
                  "type": "CategoricalVariant",
                  "name": "CD19 +",
                  "constraints": [],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Protein expression"
                    },
                    {
                      "name": "marker",
                      "value": "CD19"
                    },
                    {
                      "name": "unit",
                      "value": "status"
                    },
                    {
                      "name": "equality",
                      "value": "="
                    },
                    {
                      "name": "value",
                      "value": "Positive"
                    }
                  ]
                }
              },
              {
                "id": "bmkr.criterion:15",
                "present": false,
                "subject": {
                  "id": "bmkr:12",
                  "type": "CategoricalVariant",
                  "name": "BCR::ABL1",
                  "constraints": [
                    {
                      "type": "AdjacencyConstraint",
                      "orderKnown": true,
                      "adjoinedElements": [
                        {
                          "id": "gene:hgnc:1014",
                          "conceptType": "Gene",
                          "name": "BCR",
                          "primaryCoding": {
                            "id": "coding:hgnc:1014",
                            "code": "HGNC:1014",
                            "system": "https://genenames.org",
                            "iris": [
                              "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"
                            ]
                          },
                          "mappings": [
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ensembl:ensg00000186716",
                                "code": "ENSG00000186716",
                                "system": "https://www.ensembl.org",
                                "iris": [
                                  "https://www.ensembl.org/id/ENSG00000186716"
                                ]
                              }
                            },
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ncbi:613",
                                "code": "613",
                                "system": "https://www.ncbi.nlm.nih.gov/gene",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/gene/613"
                                ]
                              }
                            },
                            {
                              "relation": "relatedMatch",
                              "coding": {
                                "id": "coding:refseq:NM_004327.4",
                                "code": "NM_004327.4",
                                "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"
                                ]
                              }
                            }
                          ]
                        },
                        {
                          "id": "gene:hgnc:76",
                          "conceptType": "Gene",
                          "name": "ABL1",
                          "primaryCoding": {
                            "id": "coding:hgnc:76",
                            "code": "HGNC:76",
                            "system": "https://genenames.org",
                            "iris": [
                              "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"
                            ]
                          },
                          "mappings": [
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ensembl:ensg00000097007",
                                "code": "ENSG00000097007",
                                "system": "https://www.ensembl.org",
                                "iris": [
                                  "https://www.ensembl.org/id/ENSG00000097007"
                                ]
                              }
                            },
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ncbi:25",
                                "code": "25",
                                "system": "https://www.ncbi.nlm.nih.gov/gene",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/gene/25"
                                ]
                              }
                            },
                            {
                              "relation": "relatedMatch",
                              "coding": {
                                "id": "coding:refseq:NM_005157.6",
                                "code": "NM_005157.6",
                                "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"
                                ]
                              }
                            }
                          ]
                        }
                      ]
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Gene fusion"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:ema:blincyto:2",
            "type": "Indication",
            "description": "BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2025-08-29:0",
                "type": "Contribution",
                "description": "On 2025-02-10, the EMA published an EPAR - Assessment report - Variation that recommended revising this approval's from being indicated for pediatric patients aged 1 year or older to 1 month or older.",
                "date": "2025-08-29",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:ema:2025-01-23:0",
                "type": "Contribution",
                "description": "Indication received approval from the European Commission.",
                "date": "2025-01-23",
                "contributor": {
                  "id": "agent:org:ema",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "European Medicines Agency",
                  "description": "Regulatory agency that approves medicines for use in the European Union."
                }
              },
              {
                "id": "ctrb:vanallenlab:2024-10-20:0",
                "type": "Contribution",
                "description": "Adding EMA approvals for use to database",
                "date": "2024-10-20",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:ema:blincyto",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Blincyto (blinatumomab) [product information]. EMA.",
                "title": null,
                "aliases": [],
                "description": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.",
                "urls": [
                  "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf",
                  "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:ema",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "European Medicines Agency",
                      "description": "Regulatory agency that approves medicines for use in the European Union."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Amgen Europe B.V.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Blincyto",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "blinatumomab",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2015-12-07",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2025-07-23",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}